Breast Cancer Update
Summary: Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.
- Visit Website
- RSS
- Artist: Dr Neil Love
- Copyright: Copyright 2009 Research To Practice. All Rights Reserved
Podcasts:
www.BreastCancerUpdate.com/ThinkTank – Proceedings from a Clinical Investigator “Think Tank”
Interview with Eric P Winer, MD
Interview with Aman U Buzdar, MD
Tumor Panel Case Discussion: Brian Leyland-Jones, MD, PhD and Mark D Pegram, MD
Interview with Anthony Howell, MD
Interview with Soonmyung Paik, MD
Interview with Frankie Ann Holmes, MD
Interview with Eleftherios P Mamounas, MD, MPH
Interview with Andrew D Seidman, MD
Interview with Allan Lipton, MD
Interview with Robert E Marx, DDS
Most patients with ER-positive, HER2-negative, node-negative breast cancer should be presented with the option of participating in the TAILORx trial and of having the Oncotype DX assay performed outside of a trial.
For postmenopausal women with ER-positive, metastatic disease, tamoxifen, an aromatase inhibitor or fulvestrant are essentially equivalent choices.
Outside a protocol setting, dose-dense AC ->paclitaxel, administered every two weeks with growth factors, with trastuzumab during and following the paclitaxel, provides the best potential risk/benefit profile for women with HER2-positive, node-positive disease.
Neoadjuvant therapy with an aromatase inhibitor provides the best potential risk/benefit profile for postmenopausal women with HER2-negative, strongly ER-positive and PR-positive disease.
